# Gilead Sciences (GILD) total debt: $24.94B in 2025

URL: https://funkfolio.com/stock/GILD/total-debt

> Gilead Sciences (GILD) total debt was $24.94B at the end of fiscal 2025, down 6.6% from fiscal 2024. Over five fiscal years it shrank 4.5% a year.

---

## Gilead Sciences (GILD) total debt

**Total debt · fiscal 2025:** $24.94B at Dec 31, 2025

Gilead Sciences (GILD) carried total debt of $24.94B at the end of fiscal 2025 (December 31, 2025). That is 6.6% lower than the $26.71B of fiscal 2024. Figures as of 18 Nov 2026, 11:09 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Total debt, fiscal 2025:** $24.94B
- **Change on fiscal 2024:** −6.6%
- **Growth, 5 years:** −4.5% a year
- **Growth, 10 years:** +1.2% a year
- **Highest on record:** $33.54B fiscal 2017
- **Lowest on record:** $6.64B fiscal 2013
- **Fiscal years on record:** 15 2011–2025

Figures as of 18 Nov 2026, 11:09 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Gilead Sciences total debt, in more detail

Over the five fiscal years to 2025 total debt shrank at a compound 4.5% a year; over ten years the rate was 1.2% a year. Across the 15 fiscal years on record (2011–2025), the highest was $33.54B in fiscal 2017 and the lowest $6.64B in fiscal 2013.

Total debt was 1.1× shareholders' equity at the end of fiscal 2025.

### Total debt by fiscal year

### Gilead Sciences total debt, year by year

Gilead Sciences (GILD) total debt by fiscal year

| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
| --- | --- | --- | --- | --- |
| 2025 | $24.94B | 6.6% down | Dec 31, 2025 | 1.1× |
| 2024 | $26.71B | 6.9% up | Dec 31, 2024 | 1.4× |
| 2023 | $24.99B | 1.0% down | Dec 31, 2023 | 1.1× |
| 2022 | $25.23B | 5.5% down | Dec 31, 2022 | 1.2× |
| 2021 | $26.70B | 15.0% down | Dec 31, 2021 | 1.3× |
| 2020 | $31.40B | 27.7% up | Dec 31, 2020 | 1.7× |
| 2019 | $24.59B | 10.0% down | Dec 31, 2019 | 1.1× |
| 2018 | $27.32B | 18.5% down | Dec 31, 2018 | 1.3× |
| 2017 | $33.54B | 27.3% up | Dec 31, 2017 | 1.6× |
| 2016 | $26.35B | 18.8% up | Dec 31, 2016 | 1.4× |
| 2015 | $22.18B | 78.8% up | Dec 31, 2015 | 1.2× |
| 2014 | $12.40B | 86.9% up | Dec 31, 2014 | 0.8× |
| 2013 | $6.64B | 19.3% down | Dec 31, 2013 | 0.6× |
| 2012 | $8.22B | 8.1% up | Dec 31, 2012 | 0.9× |
| 2011 | $7.61B | — | Dec 31, 2011 | 1.1× |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

### How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

### Total debt at health care companies of similar size

Total debt of Gilead Sciences and comparable companies

| Company | Total debt | Fiscal year |
| --- | --- | --- |
| [Thermo Fisher Scientific TMO](https://funkfolio.com/stock/TMO/total-debt) | $39.39B | 2025 |
| [Amgen AMGN](https://funkfolio.com/stock/AMGN/total-debt) | $54.60B | 2025 |
| Gilead Sciences GILD | $24.94B | 2025 |
| [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT/total-debt) | $13.86B | 2025 |
| [Novo Nordisk NVO](https://funkfolio.com/stock/NVO/total-debt) | DKK 130.96B | 2025 |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/total-debt) | $63.96B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Gilead Sciences, figure by figure

- [Gilead Sciences market cap](https://funkfolio.com/stock/GILD/market-cap)
- [Gilead Sciences revenue](https://funkfolio.com/stock/GILD/revenue)
- [Gilead Sciences earnings](https://funkfolio.com/stock/GILD/earnings)
- [Gilead Sciences earnings per share (EPS)](https://funkfolio.com/stock/GILD/eps)
- [Gilead Sciences P/E ratio](https://funkfolio.com/stock/GILD/pe-ratio)
- [Gilead Sciences P/S ratio](https://funkfolio.com/stock/GILD/ps-ratio)
- [Gilead Sciences P/B ratio](https://funkfolio.com/stock/GILD/pb-ratio)
- [Gilead Sciences free cash flow](https://funkfolio.com/stock/GILD/free-cash-flow)
- [Gilead Sciences operating margin](https://funkfolio.com/stock/GILD/operating-margin)
- [Gilead Sciences dividend](https://funkfolio.com/stock/GILD/dividend)
- [Gilead Sciences shares outstanding](https://funkfolio.com/stock/GILD/shares-outstanding)
- [Gilead Sciences cash on hand](https://funkfolio.com/stock/GILD/cash)
- [Gilead Sciences total assets](https://funkfolio.com/stock/GILD/total-assets)
- [Gilead Sciences return on equity (ROE)](https://funkfolio.com/stock/GILD/roe)
- [Gilead Sciences return on invested capital (ROIC)](https://funkfolio.com/stock/GILD/roic)

[Gilead Sciences (GILD) overview: price, valuation and scorecard](https://funkfolio.com/stock/GILD) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Gilead Sciences total debt: questions and answers

**How much debt does Gilead Sciences have?**

Gilead Sciences (GILD) carried total debt of $24.94B at the end of fiscal 2025 (December 31, 2025). That is 6.6% lower than the $26.71B of fiscal 2024.

**What is the growth rate of Gilead Sciences's total debt?**

Over the five fiscal years to 2025 total debt shrank at a compound 4.5% a year; over ten years the rate was 1.2% a year.

**What are the highest and lowest total debt figures on record for Gilead Sciences?**

Across the 15 fiscal years on record (2011–2025), the highest was $33.54B in fiscal 2017 and the lowest $6.64B in fiscal 2013.

**How does Gilead Sciences's debt compare with its equity?**

Total debt was 1.1× shareholders' equity at the end of fiscal 2025.

**How is Gilead Sciences's total debt calculated?**

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative. For Gilead Sciences it is on record here for 15 fiscal years, 2011 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: total debt

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Gilead Sciences (GILD) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/GILD/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.
